COVID-19
Every week there are numerous scientific studies published. Here’s a look at some of the more interesting ones.
A late-stage lung cancer drug under development by OSE Immunotherapeutics met its 12-month primary endpoint for survival rates following a Step-1 analysis.
Pinpoint Therapeutics believes that its approach to treat therapy-resistant cancers also may be effective against COVID-19.
With all the similarities, it should be emphasized that there are several significant differences between the two pandemics.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for April 2, 2020.
On Wednesday, the judge overseeing Holmes’ case set for late July refused to change the trial date after her defense team made the request.
On March 25, the American Medical Association, American Pharmacist Association and Americans Society of Health-System Pharmacists issued a statement in response to media reports that physicians and pharmacists were hoarding supplies of the drugs for their own use.
The U.S. Food and Drug Administration is expediting the development of novel therapies for the pandemic through an accelerated evaluation process.
The companies initiated a Phase II/III trial in Italy, Spain, Germany, France, Japan, Canada and Russia.
The company announced today, in what has been a series of announcements, that it had filed a second clinical trial protocol with the U.S. Food and Drug Administration (FDA) to treat severely sick COVID-19 patients with COVID-19.
PRESS RELEASES